<DOC>
	<DOCNO>NCT01526434</DOCNO>
	<brief_summary>The main objective ass Health-Related Quality Life ( HRQoL ) accord physical function , measure specific Questionnaire ( Health Assessment Questionnaire ) , Rheumatoid Arthritis ( RA ) patient begin therapy subcutaneous Anti-Tumour Necrosis Factor alpha ( TNFα ) Certolizumab Pegol ( CZP ) .</brief_summary>
	<brief_title>Health-related Quality Life Patient-reported Outcomes Rheumatoid Arthritis Patients Treated With Certolizumab Pegol</brief_title>
	<detailed_description>An open-label , prospective , post-authorization observational study . This non-interventional study design establish importance measurement HRQoL data patient-reported outcome clinical practice patient RA , assess efficacy safety use CZP accord summary product characteristic .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patient male female , age 18 year old Patient active Rheumatoid Arthritis accord American College Rheumatology ( ACR ) criterion duration ≥ 3 month Patient DAS28 ( ESR ) &gt; 4.5 CRP &gt; 1.0 mg/dl Baseline Patient fail previous Disease Modifying AntiRheumatic Drugs ( DMARDs ) include Methotrexate treatment Patient initiate treatment subcutaneous antiTumour Necrosis Factor alpha ( antiTNFα ) CZP , administer every 2 week Patient prior antiTNFα treatment ( Naïve Patient ) CZP administer failure first antiTNFα treatment ( First Switch Patient ) Patient consider reliable capable adhere protocol , visit schedule medication intake accord judgment physician Patient sign date write informed consent form The patient 's treatment must within term Summary Product Characteristics ( SmPC ) Patient know hypersensitivity active substance excipients Patient active Tuberculosis severe infection Sepsis Opportunistic Infections Patient moderate severe Heart Failure ( New York Heart Association ( NHYA ) class III/IV ) Patient medical psychiatric condition , opinion physician , could jeopardize would compromise patient 's ability participate study complete schedule questionnaire Pregnant woman woman childbearing potential use adequate contraception prevent pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Cimzia</keyword>
	<keyword>Non-interventional</keyword>
	<keyword>Multicenter</keyword>
	<keyword>Postmarketing</keyword>
	<keyword>Local</keyword>
</DOC>